Karyopharm Seeks FDA Accelerated Approval for Selinexor-Ruxolitinib Combo in Myelofibrosis
Event summary
- Karyopharm submitted an sNDA to the FDA for XPOVIO (selinexor) plus ruxolitinib in myelofibrosis, seeking Accelerated Approval and Priority Review.
- The submission is based on Phase 3 SENTRY trial data showing spleen volume reduction and a promising overall survival signal.
- FDA decision on filing acceptance and review timelines expected in Q4 2026.
- Selinexor has Orphan Drug and Fast Track Designations for myelofibrosis in the U.S. and EU.
The big picture
Karyopharm's submission represents a strategic push into the myelofibrosis market, a rare blood cancer with limited treatment options beyond JAK inhibitors. The company is leveraging its XPO1 inhibitor platform to differentiate itself in a space where spleen volume reduction and symptom management are critical endpoints. Success here could expand Karyopharm's oncology portfolio beyond its current multiple myeloma indications.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept spleen volume reduction as a surrogate endpoint for Accelerated Approval.
- Clinical Validation
- The pace at which long-term overall survival data from the SENTRY trial will confirm clinical benefit.
- Commercial Strategy
- How Karyopharm will position this combination therapy in a market dominated by JAK inhibitors.
Related topics